The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs

Breast Cancer Research and Treatment

Volumn 101, Issue 1, 2007, Pages 95-104

  Fasching, Peter A ^a   Von Minckwitz, Gunter ^b   Fischer, Thorsten ^c   Kaufmann, Manfred ^d   Schultz Zehden, Beate ^e   Beck, Heike ^f   Lux, Michael P ^a   Jacobs, Volker ^c   Meden, Harald ^g   Kiechle, Marion ^c   Beckmann, Matthias W ^a   Paepke, Stefan ^c  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b GERMAN BREAST GROUP   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f Diakoniekrankenhaus ^*

^g Diakoniekrankenhaus   (Germany)

Author keywords

Breast cancer prevention; Chemoprevention; Clinical trials; Survey

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AWARENESS; BREAST CANCER; CANCER RISK; CHEMOPROPHYLAXIS; CONTROLLED STUDY; EMPLOYMENT; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; SOCIOECONOMICS; ATTITUDE TO HEALTH; BREAST TUMOR; MIDDLE AGED; PSYCHOLOGICAL ASPECT; RISK FACTOR; SOCIAL CLASS; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOPREVENTION; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MIDDLE AGED; QUESTIONNAIRES; RISK FACTORS; SOCIAL CLASS;

EID: 34250855663     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9272-2     Document Type: Article

References (37)

1. Cuzick J, Forbes J, Edwards R et al (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360:817-824
2. Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388
3. Powles T, Eeles R, Ashley S et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98-101
4. Veronesi U, Maisonneuve P, Sacchini V et al (2002) Tamoxifen for breast cancer among hysterectomised women. Lancet 359:1122-1124
5. Cauley JA, Norton L, Lippman ME et al (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125-134
6. Cuzick J, Powles T, Veronesi U et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296-300
7. Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802
8. ATAC Trialists (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131-2139
9. Thurlimann B, for the BIG 1-98 Collaborative Group X: BIG 1-98 (2005) A prospective randomized double-blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast 14(Suppl 1):S3
10. Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092
11. Jakesz R, Kaufmann M, Gnant M et al (2004) Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 88(Suppl 1):S7
12. Cuzick J (2005) Aromatase inhibitors for breast cancer prevention. J Clin Oncol 23:1636-1643
13. Siminoff LA, Zhang A, Colabianchi N et al (2000) Factors that predict the referral of breast cancer patients onto clinical trials by their surgeons and medical oncologists. J Clin Oncol 18:1203-1211
14. Lara PN Jr, Higdon R, Lim N et al (2001) Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 19:1728-1733
15. Paskett ED, Cooper MR, Stark N et al (2002) Clinical trial enrollment of rural patients with cancer. Cancer Pract 10:28-35
16. Murthy VH, Krumholz HM, Gross CP (2004) Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291:2720-2726
17. Gross CP, Murthy V, Li Y et al (2004) Cancer trial enrollment after state-mandated reimbursement. J Natl Cancer Inst 96:1063-1069
18. Gross CP, Krumholz HM (2005) Impact of managed care on cancer trial enrollment. J Clin Oncol 23:3811-3818
19. Ellis PM, Butow PN, Simes RJ et al (1999) Barriers to participation in randomized clinical trials for early breast cancer among Australian cancer specialists. Aust NZ J Surg 69:486-491
20. Ellis PM, Butow PN, Tattersall MH et al (2001) Randomized clinical trials in oncology: understanding and attitudes predict willingness to participate. J Clin Oncol 19:3554-3561
21. Simon MS, Du W, Flaherty L et al (2004) Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol 22:2046-2052
22. Gross CP, Filardo G, Mayne ST et al (2005) The impact of socioeconomic status and race on trial participation for older women with breast cancer. Cancer 103:483-491
23. Powles TJ (2002) Breast cancer prevention. Oncologist 7:60-64
24. von Minckwitz G, Prieshof B, Hofmann K et al (2002) Prevention with goserelin and ibandronate in premenopausal women with familial breast cancer risk: first experiences of the GISS study. Arch Gynecol Obstet 267(Suppl 1):S52
25. Vernon SW, Yeomans AC, Frankowski R et al (1995) Behavioral and social factors that predict participation in the Breast Cancer Prevention Trial. Ann NY Acad Sci 768:300
26. Yeomans-Kinney A, Vernon SW, Frankowski RF et al (1995) Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment. Cancer 76:46-56
27. Yeomans Kinney AY, Richards C, Vernon SW et al (1998) The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial. Prev Med 27:713-719
28. Yeomans Kinney A, Vernon SW, Shui W et al (1998) Validation of a model predicting enrollment status in a chemoprevention trial for breast cancer. Cancer Epidemiol Biomarkers Prev 7:591-595
29. Wacholder S (2004) Bias in intervention studies that enroll patients from high-risk clinics. J Natl Cancer Inst 96:1204-1207
30. Paepke S, Schubert R, Huttner C et al (2000) Breast cancer awareness and screening behavior: a cross-sectional analysis of 2110 women. Geburtshilfe Frauenheilkd 60:620-624
31. Gail MH, Brinton LA, Byar DP et al (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879-1886
32. Claus EB, Risch N, Thompson WD (1994) Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. Cancer 73:643-651
33. Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145-158
34. Antoniou AC, Pharoah PP, Smith P et al (2004) The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 91:1580-1590
35. Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23:1111-1130
36. Amir E, Evans DG, Shenton A et al (2003) Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40:807-814
37. Fasching PA, Nestle-Kraemling C, Bani M et al (2004) Breast cancer risk assessment in clinical use: prediction of BRCA mutation and estimation of lifetime risk by BRCAPRO, MENDEL and the Tyrer-Cuzick model. J Cancer Res Clin Oncol 130(Suppl):S57